Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLLISION RELAPSE trial
NL-OMON60944Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of capecitabine in colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Overall survival. Started Dec 2024; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on NL-OMON60944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60944.